ID   PIM2_HUMAN              Reviewed;         311 AA.
AC   Q9P1W9; A8K4G6; Q99739;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   15-MAR-2017, entry version 147.
DE   RecName: Full=Serine/threonine-protein kinase pim-2;
DE            EC=2.7.11.1;
DE   AltName: Full=Pim-2h;
GN   Name=PIM2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Testis;
RX   PubMed=9804974; DOI=10.1016/S0167-4781(98)00185-7;
RA   Baytel D., Shalom S., Madgar I., Weissenberg R., Don J.;
RT   "The human Pim-2 proto-oncogene and its testicular expression.";
RL   Biochim. Biophys. Acta 1442:274-285(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Ishida N., Miura N., Yamauchi M., Kawakita M.;
RT   "Genomic organization of the human UDP-galactose transporter gene.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x;
RA   Leong W.F., Chow V.T.;
RT   "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells
RT   reveal differential cellular gene expression in response to
RT   enterovirus 71 infection.";
RL   Cell. Microbiol. 8:565-580(2006).
RN   [7]
RP   FUNCTION IN PHOSPHORYLATION OF CDKN1B.
RX   PubMed=18593906; DOI=10.1158/0008-5472.CAN-08-0634;
RA   Morishita D., Katayama R., Sekimizu K., Tsuruo T., Fujita N.;
RT   "Pim kinases promote cell cycle progression by phosphorylating and
RT   down-regulating p27Kip1 at the transcriptional and posttranscriptional
RT   levels.";
RL   Cancer Res. 68:5076-5085(2008).
RN   [8]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=18675992; DOI=10.1016/j.jss.2008.03.033;
RA   Gong J., Wang J., Ren K., Liu C., Li B., Shi Y.;
RT   "Serine/threonine kinase Pim-2 promotes liver tumorigenesis induction
RT   through mediating survival and preventing apoptosis of liver cell.";
RL   J. Surg. Res. 153:17-22(2009).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF CDKN1A.
RX   PubMed=20307683; DOI=10.1016/j.biocel.2010.03.012;
RA   Wang Z., Zhang Y., Gu J.J., Davitt C., Reeves R., Magnuson N.S.;
RT   "Pim-2 phosphorylation of p21(Cip1/WAF1) enhances its stability and
RT   inhibits cell proliferation in HCT116 cells.";
RL   Int. J. Biochem. Cell Biol. 42:1030-1038(2010).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH
RP   RUTHENIUM-PYRIDOCARBAZOLE-1.
RX   PubMed=19841674; DOI=10.1371/journal.pone.0007112;
RA   Bullock A.N., Russo S., Amos A., Pagano N., Bregman H.,
RA   Debreczeni J.E., Lee W.H., von Delft F., Meggers E., Knapp S.;
RT   "Crystal structure of the PIM2 kinase in complex with an
RT   organoruthenium inhibitor.";
RL   PLoS ONE 4:E7112-E7112(2009).
RN   [11]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-138 AND VAL-280.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Proto-oncogene with serine/threonine kinase activity
CC       involved in cell survival and cell proliferation. Exerts its
CC       oncogenic activity through: the regulation of MYC transcriptional
CC       activity, the regulation of cell cycle progression, the regulation
CC       of cap-dependent protein translation and through survival
CC       signaling by phosphorylation of a pro-apoptotic protein, BAD.
CC       Phosphorylation of MYC leads to an increase of MYC protein
CC       stability and thereby an increase transcriptional activity. The
CC       stabilization of MYC exerted by PIM2 might explain partly the
CC       strong synergism between these 2 oncogenes in tumorigenesis.
CC       Regulates cap-dependent protein translation in a mammalian target
CC       of rapamycin complex 1 (mTORC1)-independent manner and in parallel
CC       to the PI3K-Akt pathway. Mediates survival signaling through
CC       phosphorylation of BAD, which induces release of the anti-
CC       apoptotic protein Bcl-X(L)/BCL2L1. Promotes cell survival in
CC       response to a variety of proliferative signals via positive
CC       regulation of the I-kappa-B kinase/NF-kappa-B cascade; this
CC       process requires phosphorylation of MAP3K8/COT. Promotes growth
CC       factor-independent proliferation by phosphorylation of cell cycle
CC       factors such as CDKN1A and CDKN1B. Involved in the positive
CC       regulation of chondrocyte survival and autophagy in the epiphyseal
CC       growth plate. {ECO:0000269|PubMed:18593906,
CC       ECO:0000269|PubMed:18675992, ECO:0000269|PubMed:20307683}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts with MYC. {ECO:0000250}.
CC   -!- INTERACTION:
CC       O75541:ZNF821; NbExp=3; IntAct=EBI-720425, EBI-740865;
CC   -!- TISSUE SPECIFICITY: Highly expressed in hematopoietic tissues, in
CC       leukemic and lymphoma cell lines, testis, small intestine, colon
CC       and colorectal adenocarcinoma cells. Weakly expressed in normal
CC       liver, but highly expressed in hepatocellular carcinoma tissues.
CC       {ECO:0000269|PubMed:18675992}.
CC   -!- INDUCTION: Down-regulated in response to enterovirus 71 (EV71)
CC       infection. {ECO:0000269|PubMed:16548883}.
CC   -!- PTM: Autophosphorylated. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. PIM subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC78506.1; Type=Frameshift; Positions=293; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U77735; AAC78506.1; ALT_FRAME; mRNA.
DR   EMBL; AK290931; BAF83620.1; -; mRNA.
DR   EMBL; AB042425; BAA95613.1; -; Genomic_DNA.
DR   EMBL; AF207550; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC018111; AAH18111.1; -; mRNA.
DR   CCDS; CCDS14312.1; -.
DR   RefSeq; NP_006866.2; NM_006875.3.
DR   UniGene; Hs.727148; -.
DR   PDB; 2IWI; X-ray; 2.80 A; A/B=1-311.
DR   PDB; 4X7Q; X-ray; 2.33 A; A/B=1-311.
DR   PDBsum; 2IWI; -.
DR   PDBsum; 4X7Q; -.
DR   ProteinModelPortal; Q9P1W9; -.
DR   SMR; Q9P1W9; -.
DR   BioGrid; 116228; 17.
DR   IntAct; Q9P1W9; 18.
DR   MINT; MINT-1432143; -.
DR   STRING; 9606.ENSP00000365692; -.
DR   BindingDB; Q9P1W9; -.
DR   ChEMBL; CHEMBL4523; -.
DR   GuidetoPHARMACOLOGY; 2159; -.
DR   iPTMnet; Q9P1W9; -.
DR   PhosphoSitePlus; Q9P1W9; -.
DR   BioMuta; PIM2; -.
DR   DMDM; 20139243; -.
DR   EPD; Q9P1W9; -.
DR   MaxQB; Q9P1W9; -.
DR   PaxDb; Q9P1W9; -.
DR   PeptideAtlas; Q9P1W9; -.
DR   PRIDE; Q9P1W9; -.
DR   DNASU; 11040; -.
DR   Ensembl; ENST00000376509; ENSP00000365692; ENSG00000102096.
DR   GeneID; 11040; -.
DR   KEGG; hsa:11040; -.
DR   UCSC; uc004dls.4; human.
DR   CTD; 11040; -.
DR   DisGeNET; 11040; -.
DR   GeneCards; PIM2; -.
DR   HGNC; HGNC:8987; PIM2.
DR   HPA; HPA000285; -.
DR   MIM; 300295; gene.
DR   neXtProt; NX_Q9P1W9; -.
DR   OpenTargets; ENSG00000102096; -.
DR   PharmGKB; PA33319; -.
DR   eggNOG; KOG0583; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000119045; -.
DR   HOGENOM; HOG000231357; -.
DR   HOVERGEN; HBG106681; -.
DR   InParanoid; Q9P1W9; -.
DR   KO; K08806; -.
DR   OMA; SDSATCP; -.
DR   OrthoDB; EOG091G0IMW; -.
DR   PhylomeDB; Q9P1W9; -.
DR   TreeFam; TF320810; -.
DR   SignaLink; Q9P1W9; -.
DR   SIGNOR; Q9P1W9; -.
DR   ChiTaRS; PIM2; human.
DR   EvolutionaryTrace; Q9P1W9; -.
DR   GeneWiki; PIM2_(gene); -.
DR   GenomeRNAi; 11040; -.
DR   PRO; PR:Q9P1W9; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000102096; -.
DR   CleanEx; HS_PIM2; -.
DR   ExpressionAtlas; Q9P1W9; baseline and differential.
DR   Genevisible; Q9P1W9; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0007140; P:male meiosis; TAS:ProtInc.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IMP:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR017348; PIM1/2/3.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF037993; STPK_Pim-1; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; ATP-binding; Cell cycle; Complete proteome;
KW   Kinase; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN         1    311       Serine/threonine-protein kinase pim-2.
FT                                /FTId=PRO_0000086532.
FT   DOMAIN       32    286       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      38     46       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    163    163       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      61     61       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   VARIANT     138    138       G -> D (in dbSNP:rs35044770).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041008.
FT   VARIANT     280    280       I -> V (in dbSNP:rs35208542).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041009.
FT   CONFLICT     66     66       N -> Y (in Ref. 2; BAF83620).
FT                                {ECO:0000305}.
FT   HELIX        28     31       {ECO:0000244|PDB:4X7Q}.
FT   STRAND       32     39       {ECO:0000244|PDB:4X7Q}.
FT   STRAND       45     51       {ECO:0000244|PDB:4X7Q}.
FT   TURN         52     54       {ECO:0000244|PDB:4X7Q}.
FT   STRAND       57     62       {ECO:0000244|PDB:4X7Q}.
FT   TURN         66     68       {ECO:0000244|PDB:2IWI}.
FT   HELIX        82     91       {ECO:0000244|PDB:4X7Q}.
FT   STRAND       97     99       {ECO:0000244|PDB:2IWI}.
FT   STRAND      102    106       {ECO:0000244|PDB:4X7Q}.
FT   STRAND      113    117       {ECO:0000244|PDB:4X7Q}.
FT   STRAND      120    124       {ECO:0000244|PDB:4X7Q}.
FT   HELIX       125    132       {ECO:0000244|PDB:4X7Q}.
FT   HELIX       137    156       {ECO:0000244|PDB:4X7Q}.
FT   HELIX       166    168       {ECO:0000244|PDB:4X7Q}.
FT   STRAND      169    172       {ECO:0000244|PDB:4X7Q}.
FT   TURN        173    176       {ECO:0000244|PDB:4X7Q}.
FT   STRAND      177    180       {ECO:0000244|PDB:4X7Q}.
FT   HELIX       183    185       {ECO:0000244|PDB:4X7Q}.
FT   HELIX       201    203       {ECO:0000244|PDB:4X7Q}.
FT   HELIX       206    211       {ECO:0000244|PDB:4X7Q}.
FT   HELIX       216    233       {ECO:0000244|PDB:4X7Q}.
FT   HELIX       241    246       {ECO:0000244|PDB:4X7Q}.
FT   HELIX       257    266       {ECO:0000244|PDB:4X7Q}.
FT   HELIX       271    273       {ECO:0000244|PDB:4X7Q}.
FT   HELIX       277    281       {ECO:0000244|PDB:4X7Q}.
FT   HELIX       284    286       {ECO:0000244|PDB:4X7Q}.
SQ   SEQUENCE   311 AA;  34190 MW;  160E56C368C67A69 CRC64;
     MLTKPLQGPP APPGTPTPPP GGKDREAFEA EYRLGPLLGK GGFGTVFAGH RLTDRLQVAI
     KVIPRNRVLG WSPLSDSVTC PLEVALLWKV GAGGGHPGVI RLLDWFETQE GFMLVLERPL
     PAQDLFDYIT EKGPLGEGPS RCFFGQVVAA IQHCHSRGVV HRDIKDENIL IDLRRGCAKL
     IDFGSGALLH DEPYTDFDGT RVYSPPEWIS RHQYHALPAT VWSLGILLYD MVCGDIPFER
     DQEILEAELH FPAHVSPDCC ALIRRCLAPK PSSRPSLEEI LLDPWMQTPA EDVPLNPSKG
     GPAPLAWSLL P
//
